krn-7000 and Influenza--Human

krn-7000 has been researched along with Influenza--Human* in 5 studies

Other Studies

5 other study(ies) available for krn-7000 and Influenza--Human

ArticleYear
A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine.
    Viruses, 2022, 05-28, Volume: 14, Issue:6

    Influenza virus infects the host and transmits through the respiratory tract (i.e., the mouth and nose); therefore, the development of intranasal influenza vaccines that mimic the natural infection, coupled with an efficient mucosal adjuvant, is an attractive alternative to current parenteral vaccines. However, with the withdrawal of cholera toxin and Escherichia coli heat-labile endotoxin from clinical use due to side effects, there are no approved adjuvants for intranasal vaccines. Therefore, safe and effective mucosal adjuvants are urgently needed. Previously, we reported that one derivative of α-Galactosylceramide (α-GalCer), 7DW8-5, could enhance the protective efficacy of split influenza vaccine by injection administration. However, the mucosal adjuvanticity of 7DW8-5 is still unclear. In this study, we found that 7DW8-5 promotes the production of secret IgA antibodies and IgG antibodies and enhances the protective efficacy of the split influenza vaccine by intranasal administration. Furthermore, co-administration of 7DW8-5 with the split influenza vaccine significantly reduces the virus shedding in the upper and lower respiratory tract after lethal challenge. Our results demonstrate that 7DW8-5 is a novel mucosal adjuvant for the split influenza vaccine.

    Topics: Adjuvants, Immunologic; Administration, Intranasal; Animals; Antibodies, Viral; Galactosylceramides; Glycolipids; Humans; Immunity, Mucosal; Influenza Vaccines; Influenza, Human; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Vaccines, Inactivated

2022
Unaltered influenza disease outcomes in swine prophylactically treated with α-galactosylceramide.
    Developmental and comparative immunology, 2021, Volume: 114

    Influenza A viruses (IAV) are a major cause of respiratory diseases in pigs. Invariant natural killer T (iNKT) cells are an innate-like T cell subset that contribute significantly to IAV resistance in mice. In the current work, we explored whether expanding and activating iNKT cells with the iNKT cell superagonist α-galactosylceramide (α-GalCer) would change the course of an IAV infection in pigs. In one study, α-GalCer was administered to pigs intramuscularly (i.m.) 9 days before infection, which systemically expanded iNKT cells. In another study, α-GalCer was administered intranasally (i.n.) 2 days before virus infection to activate mucosal iNKT cells. Despite a synergistic increase in iNKT cells when α-GalCer i.m. treated pigs were infected with IAV, neither approach reduced disease signs, lung pathology, or virus replication. Our results indicate that prophylactic use of iNKT cell agonists to prevent IAV infection is ineffective in pigs. This is significant because this type of approach has been considered for humans whose iNKT cell levels and IAV infections are more similar to those of pigs than mice.

    Topics: Animals; Galactosylceramides; Humans; Influenza A virus; Influenza, Human; Injections, Intramuscular; Lung; Lymphocyte Activation; Mice; Nasal Mucosa; Natural Killer T-Cells; Orthomyxoviridae Infections; Swine; Vaccine Efficacy; Virus Replication

2021
Augmenting Influenza-Specific T Cell Memory Generation with a Natural Killer T Cell-Dependent Glycolipid-Peptide Vaccine.
    ACS chemical biology, 2017, 11-17, Volume: 12, Issue:11

    The development of a universal vaccine for influenza A virus (IAV) that does not require seasonal modification is a long-standing health goal, particularly in the context of the increasing threat of new global pandemics. Vaccines that specifically induce T cell responses are of considerable interest because they can target viral proteins that are more likely to be shared between different virus strains and subtypes and hence provide effective cross-reactive IAV immunity. From a practical perspective, such vaccines should induce T cell responses with long-lasting memory, while also being simple to manufacture and cost-effective. Here we describe the synthesis and evaluation of a vaccine platform based on solid phase peptide synthesis and bio-orthogonal conjugation methodologies. The chemical approach involves covalently attaching synthetic long peptides from a virus-associated protein to a powerful adjuvant molecule, α-galactosylceramide (α-GalCer). Strain-promoted azide-alkyne cycloaddition is used as a simple and efficient method for conjugation, and pseudoproline methodology is used to increase the efficiency of the peptide synthesis. α-GalCer is a glycolipid that stimulates NKT cells, a population of lymphoid-resident immune cells that can provide potent stimulatory signals to antigen-presenting cells engaged in driving proliferation and differentiation of peptide-specific T cells. When used in mice, the vaccine induced T cell responses that provided effective prophylactic protection against IAV infection, with the speed of viral clearance greater than that seen from previous viral exposure. These findings are significant because the vaccines are highly defined, quick to synthesize, and easily characterized and are therefore appropriate for large scale affordable manufacture.

    Topics: Adjuvants, Immunologic; Animals; CD8-Positive T-Lymphocytes; Cycloaddition Reaction; Female; Galactosylceramides; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Mice, Inbred C57BL; Natural Killer T-Cells; Orthomyxoviridae Infections; Peptides; Solid-Phase Synthesis Techniques

2017
Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection.
    European journal of immunology, 2008, Volume: 38, Issue:7

    Invariant NKT (iNKT) cells have an indubitable role in antiviral immunity, although the mechanisms by which these cells exert their functions are not fully elucidated. With the emerging importance of high-pathogenicity influenza A virus infections in humans, we questioned whether iNKT cells contribute to immune defence against influenza A virus and whether activation of these cells influences outcome. We show that activation of iNKT cells with alpha-galactosylceramide (alpha-GC) during influenza virus infection transiently enhanced early innate immune response without affecting T cell immunity, and reduced early viral titres in lungs of C57BL/6 mice. This is accompanied by a better disease course with improved weight loss profile. Temporal changes in iNKT cells in the liver, blood and lungs suggest activation and migration of iNKT cells from the liver to the lungs in mice that were administered alpha-GC. Improvement in viral titres appears dependent on activation of iNKT cells via the intraperitoneal route since intranasal administration of alpha-GC did not have the same effect. We conclude that activation of iNKT cells enhances early innate immune response in the lungs and contribute to antiviral immunity and improved disease course in influenza A virus infection.

    Topics: Animals; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Galactosylceramides; Humans; Immunity, Innate; Inflammation Mediators; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Liver; Lung; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; T-Lymphocyte Subsets; T-Lymphocytes

2008
Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.
    Mucosal immunology, 2008, Volume: 1, Issue:3

    In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of alpha-galactosylceramide (alpha-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled alpha-GalCer by which we detect a direct interaction between NKT cells and alpha-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.

    Topics: Adjuvants, Immunologic; Administration, Intranasal; Animals; Antibody Specificity; Chemokine CXCL16; Chemokine CXCL6; Cross Reactions; Dendritic Cells; Fluorescent Dyes; Galactosylceramides; Humans; Immunoglobulin A; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Interleukin-4; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Nasal Mucosa; Natural Killer T-Cells; Receptors, CXCR; Receptors, CXCR6; Vaccination

2008